These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25774821)

  • 21. Population-based patient-reported quality of life outcomes following low-dose-rate versus high-dose-rate brachytherapy monotherapy for low-intermediate risk prostate cancer.
    Ong WL; Evans M; Papa N; Williams S; Millar J
    J Med Imaging Radiat Oncol; 2023 Oct; 67(7):789-795. PubMed ID: 37828817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE.
    Downs TM; Sadetsky N; Pasta DJ; Grossfeld GD; Kane CJ; Mehta SS; Carroll PR; Lubeck DP
    J Urol; 2003 Nov; 170(5):1822-7. PubMed ID: 14532784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer.
    Litwin MS; Gore JL; Kwan L; Brandeis JM; Lee SP; Withers HR; Reiter RE
    Cancer; 2007 Jun; 109(11):2239-47. PubMed ID: 17455209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. State-of-the-art: prostate LDR brachytherapy.
    Voulgaris S; Nobes JP; Laing RW; Langley SE
    Prostate Cancer Prostatic Dis; 2008; 11(3):237-40. PubMed ID: 18364676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The direct prognosis comparison of
    Liang Z; Yuliang C; Zhu M; Zhou Y; Wu X; Li H; Fan B; Zhou Z; Yan W
    Eur J Med Res; 2023 Jun; 28(1):181. PubMed ID: 37268989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?
    Boettcher M; Haselhuhn A; Jakse G; Brehmer B; Kirschner-Hermanns R
    BJU Int; 2012 Jun; 109(12):1824-30. PubMed ID: 21952039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact on quality of life of radical prostatectomy after initial active surveillance: more to lose?
    van den Bergh RC; de Blok W; van Muilekom E; Tillier C; Venderbos LD; van der Poel HG
    Scand J Urol; 2014 Aug; 48(4):367-73. PubMed ID: 24506062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
    Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
    BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients.
    Putora PM; Engeler D; Haile SR; Graf N; Buchauer K; Schmid HP; Plasswilm L
    Strahlenther Onkol; 2016 Mar; 192(3):182-9. PubMed ID: 26713323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of health-related quality of life between subjects treated with radical prostatectomy and brachytherapy.
    Lin YH; Lin VC; Yu TJ; Wang HP; Lu K
    J Clin Nurs; 2012 Jul; 21(13-14):1906-12. PubMed ID: 22176735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient reported outcomes among treatment modalities for prostate cancer.
    Johnson ME; Zaorsky NG; Martin JM; Ruth K; Greenberg RE; Uzzo RG; Hayes SB; Smaldone MC; Kutikov A; Viterbo R; Chen DY; Hallman MA; Sobczak ML; Horwitz EM
    Can J Urol; 2016 Dec; 23(6):8535-8545. PubMed ID: 27995848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
    Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
    Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of salvage robot-assisted laparoscopic prostatectomy for radiorecurrent prostate cancer.
    Rocco B; Cozzi G; Spinelli MG; Grasso A; Varisco D; Coelho RF; Patel VR
    Curr Urol Rep; 2012 Jun; 13(3):195-201. PubMed ID: 22430278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of health-related quality of life in patients with prostate cancer after treatment with radical retropubic prostatectomy and permanent prostate brachytherapy.
    Dragićević S; Naumović T; Soldatović I; Mićić S; Tulić C; Pekmezović T
    Urol Int; 2010; 85(2):173-179. PubMed ID: 20606405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of an assisted low-intensity programme of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: a randomized controlled trial.
    Tienforti D; Sacco E; Marangi F; D'Addessi A; Racioppi M; Gulino G; Pinto F; Totaro A; D'Agostino D; Bassi P
    BJU Int; 2012 Oct; 110(7):1004-10. PubMed ID: 22332815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate.
    Walsh PC
    J Urol; 2000 Jun; 163(6):1802-7. PubMed ID: 10799186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
    Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
    BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.